Autopsy report · NCT04498247
A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001)
Cause of deathOther
“The study was terminated based on an interim assessment of immunogenicity”
Life of this trial
- Ran for about 6 months before it stopped.
- 263 participants enrolled.
- Results were posted on the registry 10 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- Merck Sharp & Dohme LLC
- Sponsor type
- Industry
- Conditions
- Coronavirus Disease (COVID-19)
- Interventions
- V591; Placebo
- Participants
- 263
- Sites
- 9
- Countries
- Austria, Belgium, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.